Rapid communication Open Access
Like 0


Variant BA.2.86 and its descendant, JN.1, of SARS-CoV-2 are rising in incidence across Europe and globally. We isolated recent JN.1, BA.2.86, EG.5, XBB.1.5 and earlier variants. We tested live virus neutralisation of sera taken in September 2023 from vaccinated and exposed healthy persons (n = 39). We found clear neutralisation escape against recent variants but no specific pronounced escape for BA.2.86 or JN.1. Neutralisation escape corresponds to recent variant predominance but may not be causative of the recent upsurge in JN.1 incidence.


Article metrics loading...

Loading full text...

Full text loading...



  1. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28(9):1785-90.  https://doi.org/10.1038/s41591-022-01911-2  PMID: 35760080 
  2. Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86 lineages combining increased fitness and antibody evasion. bioRxiv. 2023;2023.11.20.567873 https://doi.org/10.1101/2023.11.20.567873 
  3. Yang S, Yu Y, Jian F, Song W, Yisimayi A, Chen X, et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect Dis. 2023;23(11):e457-9.  https://doi.org/10.1016/S1473-3099(23)00573-X  PMID: 37738994 
  4. Lasrado N, Collier AY, Hachmann NP, Miller J, Rowe M, Schonberg ED, et al. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86. Vaccine. 2023;41(47):6904-9.  https://doi.org/10.1016/j.vaccine.2023.10.051  PMID: 37872011 
  5. Sheward DJ, Yang Y, Westerberg M, Öling S, Muschiol S, Sato K, et al. Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses. Lancet Infect Dis. 2023;23(11):e462-3.  https://doi.org/10.1016/S1473-3099(23)00588-1  PMID: 37776877 
  6. Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Nair MS, et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023;624(7992):639-44.  https://doi.org/10.1038/s41586-023-06750-w  PMID: 37871613 
  7. Qu P, Xu K, Faraone JN, Goodarzi N, Zheng YM, Carlin C, et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip variants. bioRxiv. 2023;2023.09.11.557206 https://doi.org/10.1101/2023.09.11.557206 
  8. An Y, Zhou X, Tao L, Xie H, Li D, Wang R, et al. SARS-CoV-2 Omicron BA.2.86: less neutralization evasion compared to XBB sub-variants. bioRxiv. 2023;2023.09.26.559580 https://doi.org/10.1101/2023.09.26.559580 
  9. Hu Y, Zou J, Kurhade C, Deng X, Chang HC, Kim DK, et al. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1. Emerg Microbes Infect. 2023;12(2):2271089.  https://doi.org/10.1080/22221751.2023.2271089  PMID: 37824708 
  10. Lassaunière R, Polacek C, Utko M, Sørensen KM, Baig S, Ellegaard K, et al. Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1. Lancet Infect Dis. 2023;23(12):e509-10.  https://doi.org/10.1016/S1473-3099(23)00682-5  PMID: 37949089 
  11. Coombes NS, Bewley KR, Le Duff Y, Alami-Rahmouni N, Ryan KA, Kempster S, et al. Evaluation of the neutralising antibody response in human and hamster sera against SARS-CoV-2 variants up to and including BA.2.86 using an authentic virus neutralisation assay. bioRxiv. 2023;2023.10.21.563398 https://doi.org/10.1101/2023.10.21.563398 
  12. Khan K, Lustig G, Römer C, Reedoy K, Jule Z, Karim F, et al. Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant. Nat Commun. 2023;14(1):8078.  https://doi.org/10.1038/s41467-023-43703-3  PMID: 38057313 
  13. Uriu K, Ito J, Kosugi Y, Tanaka YL, Mugita Y, Guo Z, et al. Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant. Lancet Infect Dis. 2023;23(11):e460-1.  https://doi.org/10.1016/S1473-3099(23)00575-3  PMID: 37734391 
  14. Kaku Y, Okumura K, Padilla-Blanco M, Kosugi Y, Uriu K, Hinay AA, et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. bioRxiv. 2023;2023.12.08.570782 https://doi.org/10.1101/2023.12.08.570782 
  15. Yang S, Yu Y, Xu Y, Jian F, Song W, Yisimayi A, et al. Fast evolution of SARS-CoV-2 BA.2·86 to JN.1 under heavy immune pressure. Lancet Infect Dis. 2023;S1473-3099(23)00744-2. PMID: 38109919 
  16. Wilks S. Titertools: Tools for maximum-likelihood based titer analysis, dealing with non-detectable titers. Available from: https://github.com/shwilks/titertools
  17. R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org
  18. Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variants. bioRxiv. 2023;2023.11.26.568730 https://doi.org/10.1101/2023.11.26.568730 
  19. Roemer C, Sheward DJ, Hisner R, Gueli F, Sakaguchi H, Frohberg N, et al. SARS-CoV-2 evolution in the Omicron era. Nat Microbiol. 2023;8(11):1952-9.  https://doi.org/10.1038/s41564-023-01504-w  PMID: 37845314 
  20. Tsujino S, Deguchi S, Nomai T, Padilla-Blanco M, Plianchaisuk A, Wang L, et al. Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant. bioRxiv. 2023;2023.10.19.563209 https://doi.org/10.1101/2023.10.19.563209 
  21. Uraki R, Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Chiba S, et al. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep. 2023;42(12):113580.  https://doi.org/10.1016/j.celrep.2023.113580  PMID: 38103202 
  22. Tamura T, Mizuma K, Nasser H, Deguchi S, Padilla-Blanco M, Uriu K, et al. Virological characteristics of the SARS-CoV-2 BA.2.86 variant. bioRxiv. 2023;2023.11.02.565304 https://doi.org/10.1101/2023.11.02.565304 
  23. Herder V, Mendonca DC, Upfold N, Furnon W, Kerr K, Ilia G, et al. The SARS-CoV-2 Omicron sub-variant BA.2.86 is attenuated in hamsters. bioRxiv. 2023;2023.11.10.566576 https://doi.org/10.1101/2023.11.10.566576 
  24. Wilks SH, Mühlemann B, Shen X, Türeli S, LeGresley EB, Netzl A, et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science. 2023;382(6666):eadj0070.  https://doi.org/10.1126/science.adj0070  PMID: 37797027 

Data & Media loading...

Supplementary data

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error